AMAG AMAG Pharmaceuticals Inc.

-0.20  -1%
Previous Close 19.25
Open 19.25
Price To book 0.71
Market Cap 672243677
Shares 35,288,382
Volume 1,190,467
Short Ratio 10.46
Av. Daily Volume 822,049

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 commencement of enrollment announced June 1, 2017.
Digoxin immune fab (DIF)
Severe preeclampsia in pregnant women
NDA filing due early 2018.
Hypoactive sexual desire disorder (HSDD)
PDUFA date February 2, 2018 for sNDA filing.
Adults with iron deficiency anemia (IDA)
sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy

Latest News

  1. ETFs with exposure to AMAG Pharmaceuticals, Inc. : September 7, 2017
  2. AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President of Clinical Development
  3. AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
  4. AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
  5. AMAG Pharmaceuticals (AMAG) Down 6.6% Since Earnings Report: Can It Rebound?
  6. AMAG's Filing for Feraheme's Label Expansion Accepted by FDA
  7. AMAG Announces U.S. FDA Filing Acceptance and Six-Month Review of Feraheme® (ferumoxytol) for the Treatment of All Adult Patients With Iron Deficiency Anemia
  8. Edited Transcript of AMAG earnings conference call or presentation 3-Aug-17 12:00pm GMT
  9. AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : August 10, 2017
  10. AMAG Pharmaceuticals Appoints Oscar Sanchez as Vice President of Quality
  11. AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2
  12. AMAG Pharmaceuticals reports 2Q loss
  13. AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update
  14. AMAG Completes Feraheme® (ferumoxytol) FDA Submission for the Treatment of All Adult Patients With Iron Deficiency Anemia
  15. Investor Network: AMAG Pharmaceuticals, Inc. to Host Earnings Call
  16. Spark Therapeutics (ONCE) Worth a Look: Stock Gains 5.7%
  17. AMAG Pharmaceuticals Launches Intrarosa™ (prasterone) in the U.S. – a Novel Product to Treat Moderate to Severe Dyspareunia Due to Menopause
  18. AMAG Pharmaceuticals to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Thursday, August 3, 2017 at 8:00 a.m. ET
  19. AMAG Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMAG) : July 5, 2017
  20. AMAG Pharmaceuticals Focuses on Product Development & Buyouts